Sougata Sarkar, Vartika Srivastava and Manjushree Mohanty
Left ventricular hypertrophy is one of the commonest cardiac sign seen in hypertensive patients. According to American Heart Association and Joint National Committee VIII calcium channel blockers are first line drug in treatment of hypertension. Previous meta-analysis shows Calcium channel blocker can reduce left ventricular hypertrophy by 9-11%. The study was undertaken to evaluate and compare the efficacy of Amlodipine and Cilnidipine on Left ventricular hypertrophy and Systolic function. Total 48 patients were selected and enrolled as study participants. The patients were then divided as (1) Hypertensive group (n=22) and (2) Diabetic hypertensive group (n=26) - selected patients received either Amlodipine (2.5 to 10 mg) or cilnidipine (5 to 20 mg) with or without Angiotensin receptor blockade along with antidiabetic medication. Echocardiography report done to all selected patients at baseline and 12 months. Amlodipine and Cilnidipine, both can reduce left ventricular mass, left ventricular mass index, and relative wall thickness with statistical significance but without any clinical relevance when compared with the baseline. The total mean reduction in percentage of above parameters was more with Cilnidipine treated arm than Amlodipine. Both drugs have no effect on cardiac systolic function i.e., ejection fraction and endocardial fractional shortening. From this study it can be concluded that Cilnidipine is better in reducing left ventricular hypertrophy than Amlodipine in hypertensive patients without any deleterious action on systolic function.
PDFShare this article
Journal of Hypertension: Open Access received 614 citations as per Google Scholar report
